Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2021-01-06 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
董事会审计委员会工作细则
Governance Information Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 董事会审计委员会工作细则' which translates to 'Yunnan Watson Biotechnology Co., Ltd. Board Audit Committee Working Rules'. It details the composition, responsibilities, decision-making procedures, and rules of the Audit Committee of the Board of Directors. It references relevant laws and listing rules but does not contain any financial statements, audit opinions, or results of audits. It is a governance document outlining internal rules and procedures related to the audit committee's function within the board. It is not an audit report, annual report, or any financial report. It fits the definition of Governance Information (CGR) as it details the company's internal rules and board structure related to governance practices.
2021-01-06 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司 投资者关系管理制度' which translates to 'Yunnan Watson Biotechnology Co., Ltd. Investor Relations Management System'. It is a detailed policy document outlining the principles, objectives, responsibilities, and procedures for managing investor relations. It references relevant laws and stock exchange listing rules, describes communication methods with investors, and details the roles of company officers in investor relations. There are no financial statements, earnings data, or audit information present. The document is a governance and procedural manual related to investor relations management rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (7648 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2021-01-06 Chinese
境外发行证券及上市相关的保密及档案管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy regarding confidentiality and archival management related to the company's overseas securities issuance and listing process. It references various laws and regulations but does not contain financial data, earnings, management changes, or any report publication. It is a governance-related document outlining procedures and compliance requirements for the company and its service providers. Given the content focuses on internal rules and governance practices, the most appropriate classification is Governance Information (CGR). The document length is 2742 characters, which is relatively short but contains substantive policy text, not just an announcement or certification.
2021-01-06 Chinese
华创证券有限责任公司关于公司使用部分闲置募集资金暂时性补充流动资金之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is an independent financial advisor's verification opinion regarding the use of idle raised funds by Yunnan Watson Biotechnology Co., Ltd. It discusses the company's use of funds raised from a major asset restructuring, including detailed descriptions of fund allocation, usage, and approvals by the board and independent directors. The document references regulatory guidelines and confirms compliance and legal procedures. It is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a specialized report related to the use of raised capital funds and the independent financial advisor's opinion on this matter, which fits the category of Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive content about fundraising and capital usage, not just an announcement or certification, so it is not RPA or RNS.
2021-01-06 Chinese
关于召开2021年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice for the 2021 first extraordinary general meeting (临时股东大会) of Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, location, voting procedures (including online voting), agenda items, and attachments such as shareholder registration forms and proxy authorization forms. The content focuses on the announcement and organization of a shareholders' meeting, including proposals to be voted on, such as issuance of overseas listed foreign shares (H shares), amendments to company bylaws, election of independent directors, and appointment of auditors. There are no financial statements or earnings data presented, nor is this a transcript or presentation. The document is not a report itself but a formal notification and procedural guide for the shareholders' meeting. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length (8279 characters) and detailed procedural content support this classification with high confidence.
2021-01-06 Chinese
关于选举公司独立董事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the nomination and election of an independent director to the company's board. It details the nomination process, qualifications of the candidate, compliance with relevant laws and regulations, and the upcoming shareholder meeting for election. There are no financial statements, audit information, or detailed financial results presented. The document is focused on board/management changes, specifically the addition of an independent director. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2021-01-06 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.